520 related articles for article (PubMed ID: 27631533)
21. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
Bergsdorf C; Ottl J
Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
[TBL] [Abstract][Full Text] [Related]
22. Improving detection of rare biological events in high-throughput screens.
Murie C; Barette C; Button J; Lafanechère L; Nadon R
J Biomol Screen; 2015 Feb; 20(2):230-41. PubMed ID: 25190066
[TBL] [Abstract][Full Text] [Related]
23. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.
Annang F; Pérez-Moreno G; García-Hernández R; Cordon-Obras C; Martín J; Tormo JR; Rodríguez L; de Pedro N; Gómez-Pérez V; Valente M; Reyes F; Genilloud O; Vicente F; Castanys S; Ruiz-Pérez LM; Navarro M; Gamarro F; González-Pacanowska D
J Biomol Screen; 2015 Jan; 20(1):82-91. PubMed ID: 25332350
[TBL] [Abstract][Full Text] [Related]
24. Rethinking molecular similarity: comparing compounds on the basis of biological activity.
Petrone PM; Simms B; Nigsch F; Lounkine E; Kutchukian P; Cornett A; Deng Z; Davies JW; Jenkins JL; Glick M
ACS Chem Biol; 2012 Aug; 7(8):1399-409. PubMed ID: 22594495
[TBL] [Abstract][Full Text] [Related]
25. Non-stoichiometric inhibition in integrated lead finding - a literature review.
Klumpp M
Expert Opin Drug Discov; 2016; 11(2):149-62. PubMed ID: 26653534
[TBL] [Abstract][Full Text] [Related]
26. Enhancements of screening collections to address areas of unmet medical need: an industry perspective.
Drewry DH; Macarron R
Curr Opin Chem Biol; 2010 Jun; 14(3):289-98. PubMed ID: 20413343
[TBL] [Abstract][Full Text] [Related]
27. Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective.
Karawajczyk A; Giordanetto F; Benningshof J; Hamza D; Kalliokoski T; Pouwer K; Morgentin R; Nelson A; Müller G; Piechot A; Tzalis D
Drug Discov Today; 2015 Nov; 20(11):1310-6. PubMed ID: 26429298
[TBL] [Abstract][Full Text] [Related]
28. Using information from historical high-throughput screens to predict active compounds.
Riniker S; Wang Y; Jenkins JL; Landrum GA
J Chem Inf Model; 2014 Jul; 54(7):1880-91. PubMed ID: 24933016
[TBL] [Abstract][Full Text] [Related]
29. Applications of Biophysics in High-Throughput Screening Hit Validation.
Genick CC; Barlier D; Monna D; Brunner R; Bé C; Scheufler C; Ottl J
J Biomol Screen; 2014 Jun; 19(5):707-14. PubMed ID: 24695619
[TBL] [Abstract][Full Text] [Related]
30. Benefits of Strategic Small-Scale Targeted Screening.
Sharlow ER
Assay Drug Dev Technol; 2016 Aug; 14(6):329-32. PubMed ID: 27341343
[TBL] [Abstract][Full Text] [Related]
31. Acoustic Sample Deposition MALDI-MS (ASD-MALDI-MS): A Novel Process Flow for Quality Control Screening of Compound Libraries.
Chin J; Wood E; Peters GS; Drexler DM
J Lab Autom; 2016 Feb; 21(1):204-7. PubMed ID: 26203056
[TBL] [Abstract][Full Text] [Related]
32. An Analysis of Different Components of a High-Throughput Screening Library.
Saha A; Varghese T; Liu A; Allen SJ; Mirzadegan T; Hack MD
J Chem Inf Model; 2018 Oct; 58(10):2057-2068. PubMed ID: 30204440
[TBL] [Abstract][Full Text] [Related]
33. Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening.
Paricharak S; Méndez-Lucio O; Chavan Ravindranath A; Bender A; IJzerman AP; van Westen GJP
Brief Bioinform; 2018 Mar; 19(2):277-285. PubMed ID: 27789427
[TBL] [Abstract][Full Text] [Related]
34. Changing the HTS Paradigm: AI-Driven Iterative Screening for Hit Finding.
Dreiman GHS; Bictash M; Fish PV; Griffin L; Svensson F
SLAS Discov; 2021 Feb; 26(2):257-262. PubMed ID: 32808550
[TBL] [Abstract][Full Text] [Related]
35. A Multimodal Data Analysis Approach for Targeted Drug Discovery Involving Topological Data Analysis (TDA).
Alagappan M; Jiang D; Denko N; Koong AC
Adv Exp Med Biol; 2016; 899():253-68. PubMed ID: 27325272
[TBL] [Abstract][Full Text] [Related]
36. Diversity & tractability revisited in collaborative small molecule phenotypic screening library design.
Lahue BR; Glick M; Tudor M; Johnson SA; Diratsouian J; Wildey MJ; Burton M; Mazzola R; Wassermann AM
Bioorg Med Chem; 2020 Jan; 28(1):115192. PubMed ID: 31837897
[TBL] [Abstract][Full Text] [Related]
37. A rapid and affordable screening platform for membrane protein trafficking.
Snyder JC; Pack TF; Rochelle LK; Chakraborty SK; Zhang M; Eaton AW; Bai Y; Ernst LA; Barak LS; Waggoner AS; Caron MG
BMC Biol; 2015 Dec; 13():107. PubMed ID: 26678094
[TBL] [Abstract][Full Text] [Related]
38. Evaluating and evolving a screening library in academia: the St Jude approach.
Nishiguchi G; Das S; Ochoada J; Long H; Lee RE; Rankovic Z; Shelat AA
Drug Discov Today; 2021 Apr; 26(4):1060-1069. PubMed ID: 33453364
[TBL] [Abstract][Full Text] [Related]
39. The Screening Compound Collection: A Key Asset for Drug Discovery.
Boss C; Hazemann J; Kimmerlin T; von Korff M; Lüthi U; Peter O; Sander T; Siegrist R
Chimia (Aarau); 2017 Oct; 71(10):667-677. PubMed ID: 29070412
[TBL] [Abstract][Full Text] [Related]
40. A Guide to Run Affinity Screens Using Differential Scanning Fluorimetry and Surface Plasmon Resonance Assays.
Bergsdorf C; Wright SK
Methods Enzymol; 2018; 610():135-165. PubMed ID: 30390797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
